Trial Profile

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 19 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Varegacestat (Primary)
Indications Fibroma
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RINGSIDE
Sponsors Ayala Pharmaceuticals; Immunome

Most Recent Events

11 Aug 2026 Results presented an Immunome media release.
08 Jul 2026 Results presented an Immunome media release.
08 Jul 2026 According to an Immunome media release, company announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027. The NDA is based on results from the Phase 3 RINGSIDE trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com